A Novel Monoclonal Anti-CD81 Antibody Produced by Genetic Immunization Efficiently Inhibits Hepatitis C Virus Cell-Cell Transmission

Background and Aims Hepatitis C virus (HCV) infection is a challenge to prevent and treat because of the rapid development of drug resistance and escape. Viral entry is required for initiation, spread, and maintenance of infection, making it an attractive target for antiviral strategies. Methods Using genetic immunization, we produced four monoclonal antibodies (mAbs) against the HCV host entry factor CD81. The effects of antibodies on inhibition of HCV infection and dissemination were analyzed in HCV permissive human liver cell lines. Results The anti-CD81 mAbs efficiently inhibited infection by HCV of different genotypes as well as a HCV escape variant selected during liver transplantation and re-infecting the liver graft. Kinetic studies indicated that anti-CD81 mAbs target a post-binding step during HCV entry. In addition to inhibiting cell-free HCV infection, one antibody was also able to block neutralizing antibody-resistant HCV cell-cell transmission and viral dissemination without displaying any detectable toxicity. Conclusion A novel anti-CD81 mAb generated by genetic immunization efficiently blocks HCV spread and dissemination. This antibody will be useful to further unravel the role of virus-host interactions during HCV entry and cell-cell transmission. Furthermore, this antibody may be of interest for the development of antivirals for prevention and treatment of HCV infection.

[1]  R. Schooley,et al.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. , 2012, The Journal of infectious diseases.

[2]  R. Bartenschlager,et al.  Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses , 2006, Journal of Virology.

[3]  Christoph Sarrazin,et al.  Resistance to direct antiviral agents in patients with hepatitis C virus infection. , 2010, Gastroenterology.

[4]  A. Folgori,et al.  Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. , 2012, Journal of hepatology.

[5]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[6]  Johan Neyts,et al.  The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination , 2013, Hepatology.

[7]  M. Hiet,et al.  Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. , 2012, Gastroenterology.

[8]  Sangeeta N. Bhatia,et al.  Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system , 2010, Nature Biotechnology.

[9]  Charles M. Rice,et al.  A genetically humanized mouse model for hepatitis C virus infection , 2011, Nature.

[10]  M. Imamura,et al.  Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor , 2011, Nature Medicine.

[11]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[12]  A. Lew,et al.  DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Clayton,et al.  Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. , 2001, The Journal of general virology.

[14]  M. Charlton.  Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents — A potentially lethal cocktail , 2011, Hepatology.

[15]  G. Leroux-Roels,et al.  Anti‐CD81 antibodies can prevent a hepatitis C virus infection in vivo , 2008, Hepatology.

[16]  T. Dragic,et al.  Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry , 2006, Journal of Virology.

[17]  C. Rice,et al.  CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection , 2004, Journal of Virology.

[18]  J. McKeating,et al.  Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. , 2010, Gastroenterology.

[19]  R. Cortese,et al.  Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor* , 2003, Journal of Biological Chemistry.

[20]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[21]  R. Bartenschlager,et al.  Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. , 2008, Gastroenterology.

[22]  Olivier Poch,et al.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.

[23]  F. Penin,et al.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. , 2000, The Journal of general virology.

[24]  J. McKeating,et al.  Claudin Association with CD81 Defines Hepatitis C Virus Entry , 2010, The Journal of Biological Chemistry.

[25]  J. McKeating,et al.  Hepatoma Cell Density Promotes Claudin-1 and Scavenger Receptor BI Expression and Hepatitis C Virus Internalization , 2009, Journal of Virology.

[26]  G. Reynolds,et al.  University of Birmingham CD81 and claudin 1 coreceptor association: Role in hepatitis C virus entry , 2008 .

[27]  Eva Herrmann,et al.  The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells , 2006, Journal of Virology.

[28]  J. Dubuisson,et al.  CD81 Expression Is Important for the Permissiveness of Huh7 Cell Clones for Heterogeneous Hepatitis C Virus Infection , 2007, Journal of Virology.

[29]  Christopher T. Jones,et al.  Diverse CD81 Proteins Support Hepatitis C Virus Infection , 2006, Journal of Virology.

[30]  J. Dubuisson,et al.  Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81 , 1999, Journal of Virology.

[31]  T. Baumert,et al.  Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. , 2011, Journal of hepatology.

[32]  C. Rice,et al.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells , 2009, The Journal of general virology.

[33]  Toshiaki Maruyama,et al.  Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.

[34]  Scavenger Receptor BI Is a Key Host Factor for Hepatitis C Virus Infection Required for an Entry Step Closely Linked to CD 81 , 2009 .

[35]  Christopher T. Jones,et al.  A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo , 2012, Hepatology.

[36]  Thomas F. Baumert,et al.  Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission , 2010, Journal of Virology.

[37]  Charles M. Rice,et al.  Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.

[38]  François-Loïc Cosset,et al.  Inhibition of hepatitis C virus infection by anti‐claudin‐1 antibodies is mediated by neutralization of E2–CD81–Claudin‐1 associations , 2010, Hepatology.

[39]  Ralf Bartenschlager,et al.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.

[40]  Arvind H. Patel,et al.  Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation , 2010, The Journal of experimental medicine.

[41]  S. Pfeffer,et al.  Reconstitution of the Entire Hepatitis C Virus Life Cycle in Nonhepatic Cells , 2012, Journal of Virology.

[42]  T. Baumert,et al.  Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. , 2013, Journal of hepatology.

[43]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[44]  X. Forns,et al.  Viral hepatitis in liver transplantation. , 2012, Gastroenterology.

[45]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. McKeating,et al.  Hepatitis C Virus Induces CD81 and Claudin-1 Endocytosis , 2012, Journal of Virology.

[47]  J. Au,et al.  Evaluation of Combination Chemotherapy , 2004, Clinical Cancer Research.

[48]  G. Reynolds,et al.  University of Birmingham Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. , 2009 .

[49]  S. V. van IJzendoorn,et al.  Protein Kinase A-Dependent Step(s) in Hepatitis C Virus Entry and Infectivity , 2008, Journal of Virology.

[50]  J. McKeating,et al.  Hepatitis C virus cell‐cell transmission in hepatoma cells in the presence of neutralizing antibodies , 2007, Hepatology.

[51]  K. Watt,et al.  A Practical Guide to the Management of HCV Infection Following Liver Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  P. Schürmann,et al.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C , 2007, Proceedings of the National Academy of Sciences.

[53]  M. Ott,et al.  Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors , 2010, PLoS pathogens.